Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
Mariangela AlloccaGaia CatalanoEdoardo V SavarinoMaria ChaparroAsaf LevartovskyGeorge MichalopoulosNikos ViazisFotis S FousekisAndreas PsistakisDaniele NovielloCatarina Neto do NascimentoBenedicte CaronVassiliki KitsouGiorgos BamiasMaría José GarcíaEirini ZacharopoulouKalliopi FoteinogiannopoulouFerdinando D'AmicoIoannis KoutroubakisPierre EllulMaria TzouvalaLaurent Peyrin BirouletJoanna TorresFlavio CaprioliKonstantinos KarmirisAngeliki TheodoropoulouKonstantinos H KatsanosDimitrios K ChristodoulouGerassimos J MantzarisUri KopylovFrancisco Javier García-AlonsoSilvio DaneseFernando MagroFornari CarlaGionata FiorinoPublished in: United European gastroenterology journal (2024)
Tofacitinib was more efficacious in reducing disease progression than ustekinumab in this cohort of refractory UC patients. However, prospective head-to-head clinical trials are needed as to confirm these data.
Keyphrases
- ulcerative colitis
- clinical trial
- end stage renal disease
- rheumatoid arthritis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- optic nerve
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- electronic health record
- stem cells
- machine learning
- patient reported outcomes
- cross sectional
- phase ii
- cell therapy
- optical coherence tomography
- open label
- patient reported